Financial performance of innovation in the life sciences economy—Tracking the IPO Class through twists and turns

The IPO Class has grown over the last 8 years and continued through a COVID-19 inflection. This session tracks the financial performance and offers insights about the IPO Class, the most innovative group of the public life sciences sector.
• Have Digital Health companies joined this class?
• What impacts have SPACs had on the opportunities for innovative companies?
• What has been the impact of COVID-19 and what does the peer group look like?
• Lessons learned about the value of new and innovative therapeutics
• Debating and discussing:
• How has the signing of deals evolved with market capitalization?
• Are we seeing re-positioning given the need for COVID-19 diagnostics, therapeutics and vaccines?
• What is the likely impact on the future of the industry of this set of innovative companies?